Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma

Masaya Miyazaki, Hiroshi Nishihara, Shunsuke Terasaka, Hiroyuki Kobayashi, Shigeru Yamaguchi, Tamio Ito, Yuuta Kamoshima, Shin Fujimoto, Sadao Kaneko, Masahito Katoh, Nobuaki Ishii, Hiromi Mohri, Mishie Tanino, Taichi Kimura, Shinya Tanaka

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS)≥2), while 62 cases (53%) were negative (TS=0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS≥2) was a significant unfavorable prognostic factor (P<0.001) as well as resectability (P=0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P<0.001) and also overall patient survival (P<0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.

Original languageEnglish
Pages (from-to)268-276
Number of pages9
JournalNeuropathology
Volume34
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

O(6)-Methylguanine-DNA Methyltransferase
Methyltransferases
Glioblastoma
temozolomide
DNA
Survival Analysis
Staining and Labeling
Oligodendroglioma
Alkylating Agents
Glioma
Disease-Free Survival
Multivariate Analysis
Survival

Keywords

  • Glioblastoma
  • Immunohistochemistry
  • MGMT
  • Survival analysis
  • Temozolomide

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma . / Miyazaki, Masaya; Nishihara, Hiroshi; Terasaka, Shunsuke; Kobayashi, Hiroyuki; Yamaguchi, Shigeru; Ito, Tamio; Kamoshima, Yuuta; Fujimoto, Shin; Kaneko, Sadao; Katoh, Masahito; Ishii, Nobuaki; Mohri, Hiromi; Tanino, Mishie; Kimura, Taichi; Tanaka, Shinya.

In: Neuropathology, Vol. 34, No. 3, 01.01.2014, p. 268-276.

Research output: Contribution to journalArticle

Miyazaki, M, Nishihara, H, Terasaka, S, Kobayashi, H, Yamaguchi, S, Ito, T, Kamoshima, Y, Fujimoto, S, Kaneko, S, Katoh, M, Ishii, N, Mohri, H, Tanino, M, Kimura, T & Tanaka, S 2014, ' Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma ', Neuropathology, vol. 34, no. 3, pp. 268-276. https://doi.org/10.1111/neup.12091
Miyazaki, Masaya ; Nishihara, Hiroshi ; Terasaka, Shunsuke ; Kobayashi, Hiroyuki ; Yamaguchi, Shigeru ; Ito, Tamio ; Kamoshima, Yuuta ; Fujimoto, Shin ; Kaneko, Sadao ; Katoh, Masahito ; Ishii, Nobuaki ; Mohri, Hiromi ; Tanino, Mishie ; Kimura, Taichi ; Tanaka, Shinya. / Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma In: Neuropathology. 2014 ; Vol. 34, No. 3. pp. 268-276.
@article{6520aa14ceba48d081f0ce061ac46c05,
title = "Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma",
abstract = "Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47{\%}) were positive for MGMT with various intensities and proportions (total score (TS)≥2), while 62 cases (53{\%}) were negative (TS=0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS≥2) was a significant unfavorable prognostic factor (P<0.001) as well as resectability (P=0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P<0.001) and also overall patient survival (P<0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.",
keywords = "Glioblastoma, Immunohistochemistry, MGMT, Survival analysis, Temozolomide",
author = "Masaya Miyazaki and Hiroshi Nishihara and Shunsuke Terasaka and Hiroyuki Kobayashi and Shigeru Yamaguchi and Tamio Ito and Yuuta Kamoshima and Shin Fujimoto and Sadao Kaneko and Masahito Katoh and Nobuaki Ishii and Hiromi Mohri and Mishie Tanino and Taichi Kimura and Shinya Tanaka",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/neup.12091",
language = "English",
volume = "34",
pages = "268--276",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Immunohistochemical evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma

AU - Miyazaki, Masaya

AU - Nishihara, Hiroshi

AU - Terasaka, Shunsuke

AU - Kobayashi, Hiroyuki

AU - Yamaguchi, Shigeru

AU - Ito, Tamio

AU - Kamoshima, Yuuta

AU - Fujimoto, Shin

AU - Kaneko, Sadao

AU - Katoh, Masahito

AU - Ishii, Nobuaki

AU - Mohri, Hiromi

AU - Tanino, Mishie

AU - Kimura, Taichi

AU - Tanaka, Shinya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS)≥2), while 62 cases (53%) were negative (TS=0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS≥2) was a significant unfavorable prognostic factor (P<0.001) as well as resectability (P=0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P<0.001) and also overall patient survival (P<0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.

AB - Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O 6 -methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy. In this study, we conducted immunohistochemical analysis of 117 cases of Japanese GBM including 19 cases of GBM with oligodendroglioma component (GBMO), using a scoring system for quantitative evaluation of staining intensity and proportion of MGMT, and performed survival analysis of these patients. Immunohistochemically, 55 cases (47%) were positive for MGMT with various intensities and proportions (total score (TS)≥2), while 62 cases (53%) were negative (TS=0). The distribution of MGMT expression pattern was not affected by any clinicopathological parameters such as the histological subtype (GBM vs. GBMO), age and gender. The survival analysis of these patients revealed that the minimal expression of MGMT (TS≥2) was a significant unfavorable prognostic factor (P<0.001) as well as resectability (P=0.004). Moreover, multivariate analysis showed that minimal MGMT expression in GBM was the most potent independent predictor for progression free survival (P<0.001) and also overall patient survival (P<0.001). This is the first report employing the scoring system for both staining intensity and proportion to evaluate immunohistochemical MGMT expression in GBM. In addition, our results emphases the clinicopathological values of the immunohistochemical approach for MGMT expression in glioma patients as a routine laboratory examination.

KW - Glioblastoma

KW - Immunohistochemistry

KW - MGMT

KW - Survival analysis

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84901693194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901693194&partnerID=8YFLogxK

U2 - 10.1111/neup.12091

DO - 10.1111/neup.12091

M3 - Article

VL - 34

SP - 268

EP - 276

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 3

ER -